Aethlon Medical reports FY2023 cash $14.5M, operating expenses $12.47M; advances Hemopurifier trials

AETHLON MEDICAL INC

Cash balance $14.5M at March 31, 2023; operating expenses $12.47M, up $1.76M from $10.71M in FY2022.
COVID-19 ICU trial in India: one patient treated; second hospital (MAMC) got ethics approval in May 2023.
Oncology clinical trial planned in Australia: safety/feasibility/dose-finding in solid tumors failing anti-PD-1 antibodies.
New organ transplant initiative: testing Hemopurifier in machine perfusion to remove viruses/exosomes from harvested organs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AETHLON MEDICAL INC reported financial results for fiscal year ended March 31, 2023.

Period: fiscal year ended March 31, 2023
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the fiscal year ended March 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-23-004477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.